Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BEGAIN antisense RNA 1 (BEGAIN-AS1) is a long non-coding antisense RNA gene annotated in the human genome, transcribed from the opposite strand of the BEGAIN gene[6]. As an antisense RNA, BEGAIN-AS1 is considered a non-protein coding RNA. The precise biological and disease role of BEGAIN-AS1 has not been established in the scientific literature or current gene/protein target databases. In general, antisense RNAs function by regulating gene expression at transcriptional, post-transcriptional, or epigenetic levels, but there is no evidence that BEGAIN-AS1 itself directly modulates any particular biological pathway or serves as a therapeutic target[1][2][3][6]. Currently, BEGAIN-AS1 does not fulfill criteria for a canonical therapeutic target such as receptor, enzyme, transporter, or ion channel, and there are no drugs known to interact with it.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BEGAIN antisense RNA 1 (BEGAIN-AS1).